By replacing empirical, from-scratch architectures with a generalizable foundation model adapter framework, ViTamyloid provides a highly sensitive scalable digital pathomics toolkit, offering objective, quantitative endpoints for Alzheimer's disease clinical trials and disease subtyping.
Y. Chen, B. D. Boon, E. Engelberg-Cook et al.· medRxiv· 0 citations
TAR DNA-binding protein of 43 kDa (TDP-43) is often found in the brains of patients with Alzheimer’s disease (AD), where it co-occurs with amyloid β plaques and tau neurofibrillary tangles, and associates with accelerated cognitive decline and brain atrophy. TDP-43’s function of repressing the inclusion of cryptic exon...
Madison M. Reeves, Sara Aviles Carpintero, M. Zanovello et al.· Alzheimer's Research & Thera...· 0 citations
Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.
Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al.· Alzheimer's & Dementia· 0 citations
Using single-nucleus RNA sequencing across 109 human and 22 mouse samples spanning dorsal and ventral striatum, a comprehensive atlas of subregional neuronal specialization is provided, suggesting divergent pharmacological targets, connectivity, and disease mechanisms.
Raleigh M. Linville, Benjamin T. James, K. Galani et al.· Cell· 2 citations· ⚡1
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.